Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
jaktinib + azacitidine
- Development stage
- Unknown
- Lead developer
- Suzhou Zelgen Biopharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous, Intravenous
01
Overview
Jaktinib + azacitidine is an investigational combination therapy comprising the pan-Janus kinase (JAK) inhibitor jaktinib and the hypomethylating agent azacitidine. Jaktinib, developed by Suzhou Zelgen Biopharmaceuticals, is a small molecule that inhibits JAK1, JAK2, and JAK3, thereby modulating the JAK-STAT signaling pathway which is frequently dysregulated in myeloproliferative neoplasms. Azacitidine is a nucleoside analogue that inhibits DNA methyltransferases, leading to DNA hypomethylation and the reactivation of tumor suppressor genes. This combination is primarily being studied for the treatment of myelofibrosis, aiming to provide synergistic clinical benefits in patients who have had inadequate responses to JAK inhibitor monotherapy.
- Other names
- jaktinib and azacitidinejaktinib plus azacitidinejaktinib hydrochloride + azacitidine
02
Targets
TYK2 (Tyrosine kinase 2)JAK2 (Janus kinase 2)JAK1 (Janus kinase 1)DNMT1 (DNA (cytosine-5)-methyltransferase 1)JAK3 (Janus kinase 3)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on jaktinib + azacitidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on jaktinib + azacitidine.